P D Reaven1, J Sacks. 1. Division of Endocrinology and Metabolism (CS-111E), Carl T. Hayden Veterans Affairs Medical Center, 650 East Indian School Road, Phoenix, AZ 85012, USA. peter.reaven@med.va.gov
Abstract
AIMS/HYPOTHESIS: The goals of this study were to determine whether coronary calcium is associated with the presence of clinical cardiovascular disease in individuals with type 2 diabetes and if the measurement of abdominal aortic calcium may have an independent or added benefit as a surrogate marker for clinical vascular disease. METHODS: A cross-sectional study of subjects with type 2 diabetes enrolled in seven medical centres in the USA participating in a Veterans Affairs Cooperative Study of glycaemic control. Enrolled subjects included 309 veterans over 40 years of age with type 2 diabetes, with or without stable cardiovascular disease, who had inadequate glycaemic control (HbA(1)c>7.5%) on oral agents and/or insulin. The study assessed lifestyle behaviours, standard cardiovascular risk factors and coronary artery and abdominal aorta calcification by electron beam computed tomography. RESULTS: Subjects with coronary artery or abdominal aorta calcification present had a strikingly higher prevalence of peripheral artery disease, coronary artery disease and all combined cardiovascular disease. Prevalence of each condition increased from 5- to 13-fold with increasing quintiles of coronary artery calcification and from 2- to 3-fold with increasing abdominal aorta calcification. These associations persisted after adjustment for lifestyle behaviours and standard cardiovascular risk factors. CONCLUSIONS/ INTERPRETATION: These results support the notion that vascular calcium in type 2 diabetes provides additional information beyond that of standard risk factors in identifying the presence of cardiovascular disease. Subclinical measures of atherosclerosis such as arterial calcification may help more precisely stratify these individuals and alert healthcare providers to those individuals who have particularly accelerated atherosclerosis.
AIMS/HYPOTHESIS: The goals of this study were to determine whether coronary calcium is associated with the presence of clinical cardiovascular disease in individuals with type 2 diabetes and if the measurement of abdominal aortic calcium may have an independent or added benefit as a surrogate marker for clinical vascular disease. METHODS: A cross-sectional study of subjects with type 2 diabetes enrolled in seven medical centres in the USA participating in a Veterans Affairs Cooperative Study of glycaemic control. Enrolled subjects included 309 veterans over 40 years of age with type 2 diabetes, with or without stable cardiovascular disease, who had inadequate glycaemic control (HbA(1)c>7.5%) on oral agents and/or insulin. The study assessed lifestyle behaviours, standard cardiovascular risk factors and coronary artery and abdominal aorta calcification by electron beam computed tomography. RESULTS: Subjects with coronary artery or abdominal aorta calcification present had a strikingly higher prevalence of peripheral artery disease, coronary artery disease and all combined cardiovascular disease. Prevalence of each condition increased from 5- to 13-fold with increasing quintiles of coronary artery calcification and from 2- to 3-fold with increasing abdominal aorta calcification. These associations persisted after adjustment for lifestyle behaviours and standard cardiovascular risk factors. CONCLUSIONS/ INTERPRETATION: These results support the notion that vascular calcium in type 2 diabetes provides additional information beyond that of standard risk factors in identifying the presence of cardiovascular disease. Subclinical measures of atherosclerosis such as arterial calcification may help more precisely stratify these individuals and alert healthcare providers to those individuals who have particularly accelerated atherosclerosis.
Authors: Peter D Reaven; Dewayne Thurmond; Alisa Domb; Richard Gerkin; Matthew J Budoff; Steven Goldman Journal: Am J Cardiol Date: 2003-11-15 Impact factor: 2.778
Authors: James B Meigs; Martin G Larson; Ralph B D'Agostino; Daniel Levy; Melvin E Clouse; David M Nathan; Peter W F Wilson; Christopher J O'Donnell Journal: Diabetes Care Date: 2002-08 Impact factor: 19.112
Authors: P W Wilson; L I Kauppila; C J O'Donnell; D P Kiel; M Hannan; J M Polak; L A Cupples Journal: Circulation Date: 2001-03-20 Impact factor: 29.690
Authors: Wenchun Qu; Thuy T Le; Stanley P Azen; Min Xiang; Nathan D Wong; Terence M Doherty; Robert C Detrano Journal: Diabetes Care Date: 2003-03 Impact factor: 19.112
Authors: Craig R Walsh; L Adrienne Cupples; Daniel Levy; Douglas P Kiel; Marian Hannan; Peter W F Wilson; Christopher J O'Donnell Journal: Am Heart J Date: 2002-10 Impact factor: 4.749
Authors: Nathan D Wong; Victor A Lopez; Matthew Allison; Robert C Detrano; Roger S Blumenthal; Aaron R Folsom; Pamela Ouyang; Michael H Criqui Journal: Atherosclerosis Date: 2010-09-18 Impact factor: 5.162
Authors: Lynne E Wagenknecht; Carl D Langefeld; Barry I Freedman; J Jeffery Carr; Donald W Bowden Journal: Am J Epidemiol Date: 2007-05-09 Impact factor: 4.897
Authors: Aramesh Saremi; Robert J Anderson; Ping Luo; Thomas E Moritz; Dawn C Schwenke; Mathew Allison; Peter D Reaven Journal: Atherosclerosis Date: 2008-08-05 Impact factor: 5.162
Authors: Ryan L McKimmie; Kurt R Daniel; J Jeffrey Carr; Donald W Bowden; Barry I Freedman; Thomas C Register; Fang-Chi Hsu; Kurt K Lohman; Richard B Weinberg; Lynne E Wagenknecht Journal: Am J Gastroenterol Date: 2008-10-03 Impact factor: 10.864
Authors: Cristina Pislaru; Birgit Kantor; Randall R Kinnick; Jill L Anderson; Marie-Christine Aubry; Matthew W Urban; Mostafa Fatemi; James F Greenleaf Journal: Invest Radiol Date: 2008-04 Impact factor: 6.016